Please use this identifier to cite or link to this item:
Title: Antibiotics business: A glimpse
Authors: Bhattacharyya, B K
Sen, S K
Keywords: Streptomyces;antibiotic;pharmaceutical industry;business;broad spectrum
Issue Date: Oct-2006
Publisher: CSIR
IPC Code: Int. Cl.8 A61K31/00
Abstract: Early history of medicine is largely supported by the secondary metabolites from microorganisms. Before the introduction of antibiotics, between 1940s and 1950s, patients with bacteraemia suffered from low survival chances, and mortality from tuberculosis was well above 50%. The emergence and spread of antibiotic resistant pathogens has increased substantially over the past two decades. At the same time, the development of new antibiotics has decreased alarmingly, because pharmaceutical companies are pulling out of antibiotic research. Reasons include, the changes in regulations of elaborate drug trials, clinical preference for narrow spectrum compounds, prolonged post marketing surveillance, hence the cost of development.
Page(s): 471-476
ISSN: 0975-0967 (Online); 0972-5849 (Print)
Appears in Collections:IJBT Vol.05(4) [October 2006]

Files in This Item:
File Description SizeFormat 
IJBT 5(4) 471-476.pdf112.75 kBAdobe PDFView/Open

Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.